Answers are grounded in this paper and cite their sources.
Introduction: Type 2 diabetes mellitus (T2DM) and obesity are closely connected conditions.Therefore, the therapeutic approach should focus on treating both of them equally.In this review, we aimed to summarise the latest research on the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodiumglucose cotransporter-2 inhibitors (SGLT2 inhibitors) in the treatment of obesity in patients with type 2 diabetes.Methods: A study search was conducted from January 2020 to October 2025 across the PubMed, Scopus and Google Scholar databases using the following keywords: Type 2 diabetes mellitus, obesity, weight control, GLP-1 receptor agonists, SGLT2 inhibitors.The primary outcome of interest was whether these agents were effective in the obesity therapy in patients with type 2 diabetes.Results: Ultimately, 5 articles met the inclusion criteria in the final review of 1176 found in databases.Conclusions: This systematic review suggests that adding medications, both GLP-1 agonists and SGLT2 inhibitors, is integral to the management of overweight or obesity in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Brodziak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: